Key result
Elevated pre-therapy C-reactive protein was significantly associated with worse overall survival (HR 2.66; 95% CI 1.95-3.64; p<0.001) in patients with diffuse large B-cell lymphoma.
Why the study?
Does elevated pre-therapy CRP predict worse survival outcomes in patients with diffuse large B-cell lymphoma?
Meta-Analysis (n=3,000)
Does elevated pre-therapy CRP predict worse survival outcomes in patients with diffuse large B-cell lymphoma?
Answers are grounded in this paper and cite their sources.
Elevated pre-therapy CRP is a significant prognostic biomarker for worse overall and progression-free survival in patients with diffuse large B-cell lymphoma.
The current meta-analysis was conducted aiming to explore the association between pre-therapy CRP and DLBCL survival outcomes. We retrieved previously published studies available from PubMed, EMBASE, Web of Science, The Cochrane Library, Wanfang databases, and China National Knowledge Infrastructure databases by June 2017. A total of 12 studies composed of 3000 patients were included in this study according to our selection criteria. The pooled HRs of elevated pre-therapy CRP were 2.66 (95% CI = 1.95-3.64, p < .001) for OS while 2.19 (95% CI = 1.72-2.78, p < .001) for PFS. Sensitivity analysis and subgroup analysis indicated that CRP remained a prognostic biomarker for OS and PFS. The pooled HR was 3.01 (95% CI = 2.38-3.81, p < .001) for OS if excluding 3 heterogeneous studies, and the heterogeneity decreased from 59.6% to 11.2%. Our study revealed that pre-therapy CRP can be a potential prognostic marker for patients with DLBCL.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2018) conducted a meta-analysis in Diffuse large B-cell lymphoma (DLBCL) (n=3,000). Elevated pre-therapy C-reactive protein (CRP) vs. Non-elevated CRP was evaluated on Overall survival (OS) (HR 2.66, 95% CI 1.95-3.64, p=<0.001). Elevated pre-therapy C-reactive protein was significantly associated with worse overall survival (HR 2.66; 95% CI 1.95-3.64; p<0.001) in patients with diffuse large B-cell lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: